A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin

被引:16
作者
Barber, Gerard R.
Lauretta, Joseph
Saez, Ruben
机构
[1] Univ Colorado Hosp, Dept Pharm Serv, Denver, CO 80262 USA
[2] Lakeland Reg Med Ctr, Microbiol Lab, Lakeland, FL USA
[3] Watson Clin Ctr Canc Care & Res, Div Hematol Oncol, Lakeland, FL USA
来源
PHARMACOTHERAPY | 2007年 / 27卷 / 06期
关键词
bacteremia; daptomycin; enterococci; Enterococcus; Enterococcus gallinarum; intrinsic drug resistance; vancomycin-resistant enterococci;
D O I
10.1592/phco.27.6.927
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gram-positive pathogens are increasingly implicated in todays changing epidemiology of hospital-acquired infections. Staphylococci, streptococci, and enterococci are among the most frequently identified causes of surgical site, complicated skin-structure, and bloodstream infections. In accordance, the use of antimicrobial agents with gram-positive activity, especially those with activity against resistant organisms, has also increased. We describe a septic, neutropenic patient with bacteremia due to Enterococcus gallinarum. Therapeutic options were restricted due to resistance factors of the organism, limited guidance in the medical literature, and the patient's history and underlying condition. Despite these challenges, the patient was successfully treated with a combination of daptomycin and gentamicin and replacement of her indwelling central line. As antimicrobial stewards and diagnosticians, we must bear in mind that selective pressures exerted by the increasing use of agents with gram-positive activity may result in an increased prevalence of organisms such as E. gallinarum.
引用
收藏
页码:927 / 932
页数:6
相关论文
共 21 条
[1]  
CHOW JW, 2002, ANTIMICROBIAL THERAP, P265
[2]  
Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA
[3]  
*CUB PHARM INC, 2006, CUB DAPT INJ PACK IN
[4]   National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-April 2000, issued June 2000 [J].
Gerberding, J ;
Gaynes, R ;
Horan, T ;
Alonso-Echanove, J ;
Edwards, J ;
Emori, G ;
Fridkin, S ;
Hageman, J ;
Henderson, T ;
Lawton, R ;
Peavy, G ;
Richards, C ;
Tolson, J ;
Wages, J .
AMERICAN JOURNAL OF INFECTION CONTROL, 2000, 28 (06) :429-448
[5]   ANTIMICROBIAL SUSCEPTIBILITY PATTERNS OF COMMON AND UNUSUAL SPECIES OF ENTEROCOCCI CAUSING INFECTIONS IN THE UNITED-STATES [J].
GORDON, S ;
SWENSON, JM ;
HILL, BC ;
PIGOTT, NE ;
FACKLAM, RR ;
COOKSEY, RC ;
THORNSBERRY, C ;
JARVIS, WR ;
TENOVER, FC .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (09) :2373-2378
[6]  
GULLBERG RM, 1989, REV INFECT DIS, V11, P74
[7]  
Hsueh PR, 2000, J CLIN MICROBIOL, V38, P2450
[8]   In vitro activity of daptomycin against vancomycin-resistant enterococci of various van types and comparison of susceptibility testing methods [J].
Jorgensen, JH ;
Crawford, SA ;
Kelly, CC ;
Patterson, JE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3760-3763
[9]   Infection of central nervous system by motile Enterococcus: First case report [J].
Kurup, A ;
Tee, WSN ;
Loo, HL ;
Lin, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) :820-822
[10]   EFFECTS OF COMBINATIONS OF BETA-LACTAMS, DAPTOMYCIN, GENTAMICIN, AND GLYCOPEPTIDES AGAINST GLYCOPEPTIDE-RESISTANT ENTEROCOCCI [J].
LECLERCQ, R ;
BINGEN, E ;
SU, QH ;
LAMBERTZECHOVSKI, N ;
COURVALIN, P ;
DUVAL, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (01) :92-98